The role of specialists in managing established rheumatoid arthritis

Rheumatology

Volumn 47, Issue 3, 2008, Pages 237-238

  Scott, D L ^a   Symmons, D P M ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; STEROID;

CLINICAL PRACTICE; CLINICAL TRIAL; COMMUNITY CARE; DISEASE ACTIVITY; DISEASE CONTROL; DRUG SAFETY; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HUMAN; MEDICAL SPECIALIST; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL STANDARD; RHEUMATOID ARTHRITIS; RISK MANAGEMENT; SCORING SYSTEM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; FEMALE; GREAT BRITAIN; HUMANS; MALE; MONITORING, PHYSIOLOGIC; PATIENT CARE TEAM; PHYSICIAN'S ROLE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 39449134583     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem362     Document Type: Editorial

References (38)

1. Scott DL, Shipley M, Dawson A, Edwards S, Symmons DP, Woolf AD. The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. Br J Rheumatol 1998;37:546-54.
2. Delaney BC, Hyde CJ, McManus RJ et al. Systematic review of near patient test evaluations in primary care. Br Med J 1999;319:824-7.
3. Chakravarty, K, McDonald H, Puller T et al. BSR & BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology 2007; 27 September 2006 [Epub ahead of print].
4. Wells G, Boers M, Tugwell P. MDA Working Group. Low disease activity state in rheumatoid arthritis: Concepts and derivation of minimal disease activity. Clin Exp, Rheumatol 2006;24(Suppl 43):S52-9.
5. Mierau M, Schools M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology 2007;46:975-9.
6. Standards of care for people with inflammatory arthritis. Arthritis and Musculoskeletal Alliance, 2004.
7. MacLean CH, Louie R, Leake B et al. Ouality of care for patients with rheumatoid arthritis. J Am Med Assoc 2000;284:984-92.
8. MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH. Measuring quality in arthritis care: Methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum 2004;51:193-202.
9. MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsell S, Klippel JH. Measuring quality in arthritis care: Methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum 2004;51:193-202.
10. Kahn KL, MacLean CH, Liu H et al. Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice. Arthritis Rheum 2006;55:884-91.
11. Khanna D, Arnold EL, Pencharz JN et al. Measuring process of arthritis care: The Arthritis Foundation's quality indicator set for rheumatoid arthritis. Somin Arthritis Rheum 2006;35:211-37.
12. Bernatsky S, Feldman D, Shrier I et al. Care pathways in early rheumatoid arthritis. Can Fam Physician 2006;52:1444-5.
13. Kahn KL, MacLean CH. Liu H et al. The complexity of care for patients with rheumatoid arthritis: Metrics for better understanding chronic disease care. Med Care 2007;45:51-65.
14. Hewlett S, Kirwan JR, Mitchell K, Hogg J, Korandovych E, Paine T. Patient-initiated Hospital follow-up for rheumatoid arthritis. Rheumatology 2000;39:990-7.
15. Hewlett S, Kirwan J, Pollock J et al. Patient initiated outpatient follow up in rheumatoid arthritis: Six year randomised controlled trial. Br Med J 2005;330:171-4.
16. Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: A multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005;64:1284-8.
17. Fransen J, Stucki G, Van Riel PL. The merits of monitoring: Should we follow all our RA patients in daily clinical practice? Rheumatology 2002;41:601-4.
18. Frensen J. Stucki G, Twisk J et al. The effectiveness of a measurement-feedback system on outcome in rheumatoid arthritis: A controlled clinical trial. Ann Rheum Dis 2003;62:624-9.
19. Symmons D, Tricker K, Harrison M et al. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drug - results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial. Rheumatology 2006;45:558-65.
20. Davies LM, Fargher EA, Tricker K, Dawes P, Scott DL, Symmons D. Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis? Ann Rheum Dis 2007;66:658-63.
21. Harrison MJ, Tricker KJ, Davies L et al. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. J Rheumatol 2005;32:2330-6.
22. Vericovsky J, Huizinga TW. Rheumatoid arthritis: The goal rather than the health-care provider is key. Lancet 2006;367:450-2.
23. Aletaha D, Strand V, Smolen JS, Ward MM. Treatment-related improvemennt in physical function varies with duration of rheumatoid arthritis. A pooled analysis of clinical trial results. Ann Rheum Dis 20 July 2007 [Epub ahead of print].
24. Symmons D, Tricker K, Harrison M et al. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs - results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial. Rheumatology 2006;45:558-65.
25. Scott DL, Pugner K, Kaarela K et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000;39:122-32.
26. Scott DL, Smith C, Kingsley G. Joird damage and disability in rheumatoid arthritis: An updated systematic review. Clin Exp Rheumatol 2003;21(5 Suppl 31):S20-7.
27. van der Heijde DM, van't Hof MA, van Riel PL et al. Judging classes activity in clinical practice in rheumatoid arthritis: First step in the development of a disease, activity Ann Rheum Dis 1990;49:916-20.
28. van der Heijde DM, van't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring diseasis activity in rheumatoid arthritis. Ann Rheum Dis 1992;51:177-81.
29. Symmons DP, Hassell AB, Gunatillaka KA, Jones PJ, Schollum J, Dawes PT. Development and preliminary assessment of a simple measure of overalt status in rheumatoid arthritis (OSRA) for routine clinical use. Q J Med 1995;88:429-37.
30. Harrison MJ, Hassell A, Dawes PT et al. The overall status in rheumatoid arthritis (OSRA) measure - further evidence to support its use in clinical practice. Rheumatology 2007;46:849-55.
31. Klarsskog L, Gaubitz M, Rodriguez-Valverde V et al. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease modifying antirheumatic drugs. Ann Rheum Dis 2006;65:1578-84.
32. Moreland LW, Weinblatt ME, Keystone EC et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-61.
33. Schiff MH, Yu EB, Weinblatt ME et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: Patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging 2006;23:167-78.
34. van der Heijde D, Klareskog L, Rodriguez-Valverde V et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
35. Vander Cruyssen B, Van Looy S, Wyns B et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: Attrition and long-term evolution of disease activity. Arthritis Res Ther 2006;8:R112.
36. Chen YF, Jobanputra P, Barton P et al. A systematic review of the effectiveness of adalimumab, etenercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10:1-229.
37. Bertele' V, Assisi A, Di Muzio V, Renzo D, Garattini S. New antirheumatic drugs: Any real added value? A critical overview of regulatory criteria for their marketing approval. Eur J Clin Pharmacol 2007;63:879-89.
38. Lempp H, Scott DL, Kingsley GH. Patients' views on the quality of health care for rheumatoid arthritis. Rheumatology 2006;45:1522-8.